[go: up one dir, main page]

WO2018190383A1 - Liquide de dispersion contenant un dispersant pour pigments ou poudres - Google Patents

Liquide de dispersion contenant un dispersant pour pigments ou poudres Download PDF

Info

Publication number
WO2018190383A1
WO2018190383A1 PCT/JP2018/015275 JP2018015275W WO2018190383A1 WO 2018190383 A1 WO2018190383 A1 WO 2018190383A1 JP 2018015275 W JP2018015275 W JP 2018015275W WO 2018190383 A1 WO2018190383 A1 WO 2018190383A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
acid
extract
membered ring
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2018/015275
Other languages
English (en)
Japanese (ja)
Inventor
瑞希 坂田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nissan Chemical Corp
Original Assignee
Nissan Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nissan Chemical Corp filed Critical Nissan Chemical Corp
Priority to JP2019512559A priority Critical patent/JPWO2018190383A1/ja
Publication of WO2018190383A1 publication Critical patent/WO2018190383A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86—Polyethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up

Definitions

  • the present invention relates to a dispersion containing a pigment or a powder dispersant, and in particular, to a dispersion containing a pigment or powder dispersant made of a lipid peptide type compound and the pigment or powder dispersant.
  • the water-based composition has a high refreshing feeling when applied to the skin, etc., and has a sticky feeling after use compared to the oil-based composition.
  • New products have been put on the market and proposed.
  • a solid aqueous composition conventionally, a solid oil-in-water makeup cosmetic (Patent Document 1) containing water, fatty acid soap, oil and powder, alkyl and / or alkenyl oligoglycoside, oily substance, and nonionic property
  • Patent Document 2 containing an emulsifier has been proposed.
  • liquid aqueous compositions there have been many proposals of water-based cosmetics containing water as the main ingredient and various additives such as moisturizers, and emulsion-type compositions containing oily ingredients and aqueous ingredients with emulsifiers. Has been.
  • aqueous cosmetics for example, many products containing various pigments and powders for coloring the skin have been proposed, but when these aqueous cosmetics are left standing for a long period of time, the pigments and powders are separated. ⁇ Sedimentation and in some cases hard cake. Therefore, proposals to stabilize dispersions by blending various resins, thickeners, dispersants, and other additives have been studied, and the separation and sedimentation of pigments and powders, as well as the aggregation and solidification of them, are being investigated. Technical proposals that can be controlled are required.
  • the present invention has been made on the basis of the above circumstances, and the problem to be solved is a dispersion and a dispersing agent capable of preventing separation and settling of pigments and the like over time in a dispersion containing pigment or powder. Is to provide.
  • the present inventors have found that a dispersion using a lipid peptide type compound comprising a low-molecular-weight lipid peptide or a pharmaceutically usable salt thereof as a dispersant for pigments or powders
  • the inventors have found that a dispersion in which separation and sedimentation with time in the blended pigments and the like are suppressed can be obtained, and the present invention has been completed.
  • the present invention provides the first aspect as follows: A surfactant, water and, A pigment or powder dispersant comprising a lipid peptide type compound comprising at least one of the compounds represented by the following formulas (1) to (3) or a pharmaceutically usable salt thereof: 1,2-alkanediol or 1,3-alkanediol; At least one fatty acid, Including at least one selected from the group consisting of pigments and powders, Concerning the dispersion.
  • R 1 represents an aliphatic group having 9 to 23 carbon atoms
  • R 2 represents a hydrogen atom or an alkyl group having 1 to 4 carbon atoms which may have a branched chain having 1 or 2 carbon atoms
  • R 3 represents a — (CH 2 ) n—X group, n represents a number of 1 to 4, X represents an amino group, a guanidino group, a —CONH 2 group, or 1 to 3 nitrogen atoms.
  • R 4 represents an aliphatic group having 9 to 23 carbon atoms
  • R 5 to R 7 each independently represents a hydrogen atom, or a carbon atom number that can have a branched chain having 1 or 2 carbon atoms.
  • R 5 to R 7 represents — (CH 2 ) n—X groups
  • n is 1 to 4 X represents an amino group, a guanidino group, a —CONH 2 group, or a 5- or 6-membered ring having 1 to 3 nitrogen atoms, or a condensed heterocycle composed of a 5-membered ring and a 6-membered ring.
  • R 8 represents an aliphatic group having 9 to 23 carbon atoms
  • R 9 to R 12 each independently represents a hydrogen atom, or the number of carbon atoms that may have a branched chain having 1 or 2 carbon atoms.
  • the dispersion according to the first aspect wherein at least one selected from the group consisting of the pigment and the powder is contained in a proportion of 25% by mass or less based on the total mass of the dispersion.
  • the pigment or the dispersant for powder is included in a ratio of 0.01% by mass to 1% by mass based on the total mass of the dispersion, described in the first aspect or the second aspect.
  • Dispersion As a 4th viewpoint, it is related with the dispersion liquid as described in any one of the 1st viewpoint thru
  • the surfactant is one or more compounds selected from the group consisting of ethylene glycol alkyl ethers, phospholipids, polyglycerin fatty acid esters, and polyoxyethylene polyoxypropylene alkyl ethers.
  • or 5th viewpoint It is related with the dispersion liquid as described in any one.
  • the present invention relates to the dispersion according to any one of the first to sixth aspects, in which the fatty acid is stearic acid.
  • it is related with the dispersion liquid as described in any one among the 1st viewpoint thru
  • the present invention relates to a pigment or a powder dispersant composed of a lipid peptide compound composed of at least one of the compounds represented by the following formulas (1) to (3) or a pharmaceutically usable salt thereof.
  • R 1 represents an aliphatic group having 9 to 23 carbon atoms
  • R 2 represents a hydrogen atom or an alkyl group having 1 to 4 carbon atoms which may have a branched chain having 1 or 2 carbon atoms
  • R 3 represents a — (CH 2 ) n—X group, n represents a number of 1 to 4,
  • X represents an amino group, a guanidino group, a —CONH 2 group, or 1 to 3 nitrogen atoms.
  • R 4 represents an aliphatic group having 9 to 23 carbon atoms
  • R 5 to R 7 each independently represents a hydrogen atom, or a carbon atom number that can have a branched chain having 1 or 2 carbon atoms.
  • R 5 to R 7 represents — (CH 2 ) n—X groups
  • n is 1 to 4 X represents an amino group, a guanidino group, a —CONH 2 group, or a 5- or 6-membered ring having 1 to 3 nitrogen atoms, or a condensed heterocycle composed of a 5-membered ring and a 6-membered ring.
  • R 8 represents an aliphatic group having 9 to 23 carbon atoms
  • R 9 to R 12 each independently represents a hydrogen atom, or the number of carbon atoms that may have a branched chain having 1 or 2 carbon atoms.
  • R 9 to R 12 represents — (CH 2 ) n—X groups
  • n is 1 to 4 X represents an amino group, a guanidino group, a —CONH 2 group, or a 5- or 6-membered ring having 1 to 3 nitrogen atoms, or a condensed heterocycle composed of a 5-membered ring and a 6-membered ring. Represents a ring.
  • the pigments and powders can be stably dispersed without being separated or settled from the dispersion over time. It can be set as the made dispersion liquid.
  • a stably dispersed dispersion can be prepared even when 10% by mass or more of the pigment is blended or when a relatively large powder such as a gold foil is blended.
  • the lipid peptide compound constituting the dispersant of the present invention is a very safe artificial low molecular weight compound composed only of lipid and peptide.
  • various components contained as additives in the dispersion of the present invention are general-purpose additives as additives for foods, cosmetics, and pharmaceuticals. That is, the dispersion of the present invention has high biological safety, and is particularly useful in the above applications from the viewpoint of safety required for pharmaceuticals and cosmetics.
  • the dispersion of the present invention is expected to be a dispersion with good refreshing feeling and elongation when applied to human skin or the like, and is a liquid base containing pigments and powders for pharmaceuticals and cosmetics. It can be expected to be used as a material and is very useful.
  • FIG. 1 shows the formulation of 10% by mass of pigments prepared in Examples 1 to 3 and Comparative Example 1 (Example 1, Example 2 and Comparative Example 1) and 15% by mass of pigment (Example 3). It is a figure which shows an external appearance.
  • FIG. 2 is a view showing the appearance of a dispersion liquid containing a pearl pigment prepared in Example 4, Example 5, and Comparative Example 2.
  • FIG. 3 is a view showing the appearance of a dispersion liquid containing tricalcium phosphate prepared in Example 6 and Comparative Example 3.
  • FIG. 4 is a view showing the appearance of a dispersion of gold foil blends prepared in Example 7, Example 8, and Comparative Example 4.
  • FIG. 1 shows the formulation of 10% by mass of pigments prepared in Examples 1 to 3 and Comparative Example 1 (Example 1, Example 2 and Comparative Example 1) and 15% by mass of pigment (Example 3). It is a figure which shows an external appearance.
  • FIG. 2 is a view showing the appearance of a dispersion liquid containing a pearl pigment prepared in Example
  • FIG. 5 is a view showing an observation result (photograph) of a polarizing microscope of the O / W liquid foundation prepared in Example 9 and Comparative Example 5.
  • FIG. 6 is a view showing the appearance of the O / W liquid foundation prepared in Example 9 and Comparative Example 5 after one month of preparation.
  • the present invention relates to a pigment comprising a lipid peptide compound comprising a surfactant, water, and a compound represented by the following formulas (1) to (3) or a pharmaceutically usable salt thereof: Or a dispersion containing a dispersant for powder, 1,2-alkanediol or 1,3-alkanediol, fatty acid, at least one selected from the group consisting of pigments and powder, and optionally other additives. Regarding liquids.
  • the present invention is also directed to a pigment or powder dispersant comprising the lipid peptide type compound.
  • each component will be described.
  • the lipid peptide type compound used as the pigment or powder dispersant of the present invention is a compound (lipid peptide) represented by the following formulas (1) to (3) or a pharmaceutically usable salt thereof (hydrophobic)
  • a low molecular compound having a lipid part as a site and a peptide part as a hydrophilic site can be used.
  • R 1 represents an aliphatic group having 9 to 23 carbon atoms, and preferably R 1 is a straight chain having 11 to 23 carbon atoms which may have 0 to 2 unsaturated bonds.
  • An aliphatic group is desirable.
  • Specific examples of the lipid moiety (acyl group) composed of a carbonyl group adjacent to R 1 include lauroyl group, dodecylcarbonyl group, myristoyl group, tetradecylcarbonyl group, palmitoyl group, margaroyl group, oleoyl group, and elideoyl group.
  • Examples include lauroyl group, myristoyl group, palmitoyl group, margaroyl group, stearoyl group, oleoyl group, elidoyl group, and behenoyl group.
  • R 2 contained in the peptide part represents a hydrogen atom or an alkyl group having 1 to 4 carbon atoms which may have a branched chain having 1 or 2 carbon atoms.
  • the alkyl group having 1 to 4 carbon atoms that may have a branched chain having 1 or 2 carbon atoms is a branched chain having 1 to 4 carbon atoms in the main chain and 1 or 2 carbon atoms.
  • Means an alkyl group which may have, and specific examples thereof include methyl group, ethyl group, n-propyl group, i-propyl group, n-butyl group, i-butyl group, sec-butyl group or tert-butyl group Etc.
  • R 2 is preferably a hydrogen atom or an alkyl group having 1 to 3 carbon atoms which may have a branched chain having 1 carbon atom, and more preferably a hydrogen atom.
  • the alkyl group having 1 to 3 carbon atoms which can have a branched chain having 1 carbon atom is an alkyl group having 1 to 3 carbon atoms in the main chain and having a branched chain having 1 carbon atom.
  • a methyl group an ethyl group, an n-propyl group, an i-propyl group, an i-butyl group, or a sec-butyl group, preferably a methyl group, an i-propyl group, An i-butyl group or a sec-butyl group.
  • R 3 represents a — (CH 2 ) n—X group.
  • n represents a number of 1 to 4
  • X is an amino group, a guanidino group, a —CONH 2 group, or a 5-membered cyclic group having 1 to 3 nitrogen atoms.
  • X is preferably an amino group, guanidino group, carbamoyl group (—CONH 2 group), pyrrole group, imidazole group, pyrazole group or indole group, and more Preferably it is an imidazole group.
  • n is preferably 1 or 2, and more preferably 1.
  • the — (CH 2 ) n- group is preferably an aminomethyl group, 2-aminoethyl group, 3-aminopropyl group, 4-aminobutyl group, carbamoylmethyl group, 2-carbamoylethyl group, 3-carbamoyl group.
  • a lipid peptide particularly suitable as a lipid peptide type compound is a compound formed from the following lipid part and peptide part (amino acid assembly part).
  • amino acids alanine (Ala), asparagine (Asn), glutamine (Gln), glycine (Gly), histidine (His), isorosine (Ile), leucine (Leu), lysine (Lys), tryptophan (Trp) ), Valine (Val).
  • Lauroyl-Gly-His Lauroyl-Gly-Gln, Lauroyl-Gly-Asn, Lauroyl-Gly-Trp, Lauroyl-Gly-Lys, Lauroyl-Ala-His, Lauroyl-Ala-Gln, Lauroyl-Ala-Asn, Lauroyl -Ala-Trp, Lauroyl-Ala-Lys; Myristoyl-Gly-His, Myristoyl-Gly-Gln, Myristoyl-Gly-Asn, Myristoyl-Gly-Trp, Myristoyl-Gly-Lys, Myristoyl-Ala-His, Myristoyl-Ala -Gln, Myristoyl-Ala-Asn, Myristoyl-Ala-Trp, Myristoyl-Ala-Lys; Palmitoyl-Gly-His, Palmitoyl-Gly-Gln, Palmi
  • lauroyl-Gly-His lauroyl-Ala-His-myristoyl-Gly-His, myristoyl-Ala-His; palmitoyl-Gly-His, palmitoyl-Ala-His; stearoyl-Gly-His, stearoyl-Ala -His.
  • R 4 represents an aliphatic group having 9 to 23 carbon atoms, and preferred specific examples include the same groups as defined for R 1 above.
  • R 5 to R 7 each independently represent a hydrogen atom, an alkyl group having 1 to 4 carbon atoms which may have a branched chain having 1 or 2 carbon atoms, or — ( CH 2 ) nX group, and at least one of R 5 to R 7 represents a — (CH 2 ) nX group.
  • n a number of 1 to 4
  • X represents an amino group, a guanidino group, a —CONH 2 group, or a 5-membered cyclic group or a 6-membered cyclic group which may have 1 to 3 nitrogen atoms, or a 5-membered ring And a condensed heterocyclic group composed of a 6-membered ring.
  • R 5 to R 7 include the same groups as defined for R 2 and R 3 above.
  • a preferable lipid peptide is a compound formed from the following lipid part and peptide part (amino acid assembly part).
  • lauroyl-Gly-Gly-His lauroyl-Gly-Gly-Gln, lauroyl-Gly-Gly-Asn, lauroyl-Gly-Gly-Trp, lauroyl-Gly-Gly-Lys, lauroyl-Gly-Ala-His, Lauroyl-Gly-Ala-Gln, Lauroyl-Gly-Ala-Asn, Lauroyl-Gly-Ala-Trp, Lauroyl-Gly-Ala-Lys, Lauroyl-Ala-Gly-His, Lauroyl-Ala-Gly-Gln, Lauroyl- Ala-Gly-Asn, Lauroyl-Ala-Gly-Trp, Lauroyl-Ala-Gly-Gly-His, Lauroyl-A
  • lauroyl-Gly-Gly-His myristoyl-Gly-Gly-His, palmitoyl-Gly-Gly-His, palmitoyl-Gly-His-Gly, palmitoyl-His-Gly-Gly, stearoyl -Gly-Gly-His.
  • R 8 represents an aliphatic group having 9 to 23 carbon atoms, and preferred specific examples include the same groups as defined for R 1 above.
  • R 9 to R 12 are each independently a hydrogen atom, an alkyl group having 1 to 4 carbon atoms which may have a branched chain having 1 or 2 carbon atoms, or — ( CH 2 ) nX group, and at least one of R 9 to R 12 represents a — (CH 2 ) nX group.
  • n a number of 1 to 4
  • X represents an amino group, a guanidino group, a —CONH 2 group, or a 5-membered cyclic group or a 6-membered cyclic group which may have 1 to 3 nitrogen atoms, or a 5-membered ring And a condensed heterocyclic group composed of a 6-membered ring.
  • R 9 to R 12 include the same groups as defined for R 2 and R 3 above.
  • particularly preferred lipid peptides include lauroyl-Gly-Gly-Gly-His, myristoyl-Gly-Gly-Gly-His, palmitoyl. -Gly-Gly-Gly-His, Palmitoyl-Gly-Gly-His-Gly, Palmitoyl-Gly-His-Gly-Gly, Palmitoyl-His-Gly-Gly-Gly, Stearoyl-Gly-Gly-Gly-His, etc. Can be mentioned.
  • the amount of the lipid peptide type compound that is a pigment or a dispersant for powder is, for example, 0.01% by mass to 1% by mass, or 0.01% by mass with respect to the total mass of the resulting dispersion. These are less than 1% by mass, preferably 0.05% by mass to 0.5% by mass, more preferably 0.05% by mass to 0.3% by mass, for example 0.05% by mass to 0.2% by mass.
  • the lipid peptide type compound used in the present invention comprises at least one of the compounds represented by the above formulas (1) to (3) (lipid peptide) or a pharmaceutically usable salt thereof, These compounds can be used alone or in combination of two or more as a dispersant for powder.
  • surfactant used in the dispersion of the present invention, a compound having a hydrophilic part and a hydrophobic part in the molecule, and the hydrophilic part having a betaine structure (hereinafter also referred to as a betaine compound), ethylene glycol alkyl ether, Polyglycerin fatty acid ester or polyoxyethylene polyoxypropylene alkyl ether can be preferably used.
  • betaine compounds as described above include N-alkyl-N, N-dimethylamino acid betaines such as lauryldimethylaminoacetic acid betaine (lauryl betaine); fatty acid amide alkyl-N such as cocamidopropyl betaine and lauramidopropyl betaine.
  • N-dimethylamino acid betaine N-dimethylamino acid betaine; imidazoline-type betaines such as sodium cocoamphoacetate and sodium lauroamphoacetate; alkylsulfobetaines such as laurylhydroxysulfobetaine and alkyldimethyltaurine; sulfate-type betaines such as alkyldimethylaminoethanol sulfate; alkyldimethylaminoethanol Known betaine compounds such as phosphate-type betaines such as phosphate esters can be used as amphoteric surfactants.
  • betaine compounds include phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidylglycerol, diphosphatidylglycerol (cardiolipin), phosphatidic acid and other glycerophospholipids; lysophosphatidylcholine (lysolecithin), lysophosphatidylethanolamine, Examples thereof include lysoglycerophospholipids such as serine, lysophosphatidylinositol, lysophosphatidylglycerol, and lysophosphatidic acid; sphingophospholipids such as sphingomyelin; and hydrogenated products thereof.
  • phospholipids may be derived from animals and plants such as soybeans and egg yolks, or may be synthesized by a chemical or enzymatic method.
  • betaine compounds preferably lauryldimethylaminoacetic acid betaine, lauric acid amidopropyl betaine, lauryl hydroxysulfobetaine, stearyl betaine, lysophosphatidylcholine (lysolecithin), lysophosphatidylethanolamine, lysophosphatidylserine, lysophosphatidylinositol, lyso Examples thereof include phosphatidylglycerol and lysophosphatidic acid, and more preferably lysophosphatidylcholine (lysolecithin).
  • ethylene glycol alkyl ether examples include polyoxyethylene alkyl ether, polyoxyethylene lauryl ether, polyoxyethylene palmitoyl ether, polyoxyethylene stearyl ether and the like. Also, commercially available ethylene glycol alkyl ethers can be used. Examples of such products include Emulgen 102KG, Emargen 103, and Emulgen 104P in Kao's Emulgen (registered trademark) series and Emanon (registered trademark) series.
  • Emulgen 103 More preferably, Kao's Emulgen 103, Emulgen 104P, Emulgen 105, Emulgen 106, Emulgen 108, Emulgen 109P, Emulgen 210P, Emulgen 306P, Emulgen 320P, Emulgen 404, Emulgen 408, Emulgen 409PV, Emulgen 420, Emulgen 705 , Emulgen 707, Emulgen 709, Emulgen 1108, Emulgen 2020G-HA, Emanon 1112, Emanon 4110.
  • Emulgen 104P More preferably, Kao's Emulgen 104P, Emulgen 105, Emulgen 106, Emulgen 108, Emulgen 210P, Emulgen 306P, Emulgen 408, Emulgen 409PV, Emulgen 705, Emulgen 707, Emulgen 709, Emulgen 1108, Emulgen 2020G-HA, Emanon 1112, Emanon 4110.
  • it can be appropriately selected from the NIKKOL (registered trademark) series of Nikko Chemicals.
  • NIKKOL BT-5, NIKKOL BT-7, NIKKOL BT-9, NIKKOL BT-12, NIKKOL BL-2, NIKKOL BL-4.2, NIKKOL BL-9EX, etc. most preferably NIKOL BL-9EX 4.2.
  • polyglycerin fatty acid ester examples include glyceryl stearate, glyceryl isostearate, glyceryl palmitate, glyceryl myristate, glyceryl oleate, glyceryl coconut oil fatty acid, mono-cotton oil fatty acid glycerin, glyceryl monosulcate, glyceryl sesquioleate, ⁇ , ⁇ '-Glycerin fatty acid partial esters such as glyceryl oleate, glyceryl monostearate, and malic monostearate; polyglyceryl stearate-2, 3, 4, 5, 6, 6, 8, 10 polyglyceryl distearate 6, same 10, polyglyceryl tristearate-2, polyglyceryl 10 decastearate, polyglyceryl-2 isostearate 3, 3, 4, 5, 6, 8, 8, 10 Liglyceryl-2 (diglyceryl diisostearate), 3, 10 (decaglyceryl diisostearate
  • Polyoxyethylene polyoxypropylene alkyl ethers include Kao's Emulgen (registered trademark) LS-106, Emulgen LS-110, Emulgen LS-114, Emulgen MS-110, and Nikko Chemicals' NIKKOL (registered) Trademarks) PBC-31, NIKKOL PBC-33, NIKKOL PBC-34, NIKKOL PBC-41, NIKKOL PBC-44, NIKKOL PBN-4612, NIKKOL PBN-4620, NIKKOL PBN-4630. More preferred are Emulgen LS-106, Emulgen LS-110, Emulgen LS-114, and Emulgen MS-110. More preferred are Emulgen LS-106, Emulgen LS-110, and Emulgen MS-110.
  • HLB Hydrophile-Lipophile Balance
  • surfactants include sorbitan isostearate, steareth-8, behenez-10, laureth-4, laureth-5, ceteth-7, oleth-8, PEG-8 glyceryl isostearate, choles-10, isostearic acid Acid PEG-10BG, PEG-30 glyceryl triisostearate, PEG-30 glyceryl triisostearate, PEG-30 glyceryl trioleate, PEG-30 triisostearate PEG-30, hydrogenated castor oil lauric acid PEG-30, PCA PEG-30 isostearic acid hydrogenated castor oil, octyldedes-10, PEG-12 dilaurate, sorbes-40 tetraoleate, polyglyceryl-10 di
  • the compounding amount of the surfactant is, for example, 0.01% by mass to 2% by mass, or, for example, 0.01% by mass to 1% by mass, preferably 0% with respect to the total mass of the resulting dispersion. 0.01 mass% to 0.5 mass%, more preferably 0.01 mass% to 0.3 mass%, for example 0.02 mass% to 0.2 mass%.
  • the surfactant used in the present invention is at least one of the above-mentioned surfactant group, and these surfactants can be used alone or in combination of two or more.
  • the 1,2-alkanediol or 1,3-alkanediol used in the dispersion of the present invention has a function of promoting the solubility of the lipid peptide type compound which is the pigment or powder dispersant.
  • Specific examples of the 1,2-alkanediol include 1,2-pentanediol, 1,2-hexanediol, 1,2-octanediol, 1,2-decanediol, and the like. Preferred are 1,2-pentanediol, 1,2-hexanediol, and 1,2-octanediol.
  • 1,2-pentanediol or 1,2-hexanediol More preferred is 1,2-pentanediol or 1,2-hexanediol.
  • Specific examples of the 1,3-alkanediol include 1,3-propanediol, 2-methyl-1,3-propanediol, 1,3-butanediol, 3-methyl-1,3-butanediol, , 3-pentanediol, 1,3-hexanediol, 2-ethyl-1,3-hexanediol, 2-ethyl-1,3-octanediol, 1,3-decanediol, and the like.
  • 1,3-butanediol 1,3-pentanediol, 1,3-hexanediol, 2-ethyl-1,3-hexanediol, and 2-ethyl-1,3-octanediol. More preferred are 1,3-butanediol, 2-ethyl-1,3-hexanediol, and 2-ethyl-1,3-octanediol. These 1,2-alkanediols or 1,3-alkanediols can be used alone or in combination of two or more.
  • the blending amount of 1,2-alkanediol or 1,3-alkanediol is, for example, 0.001% by mass to 15% by mass, preferably 0.001% by mass with respect to the total mass of the resulting dispersion.
  • 005 mass% to 15 mass% more preferably 0.01 mass% to 15 mass%, for example 0.01 mass% to 12 mass%.
  • the fatty acid used in the dispersion of the present invention is preferably at least one selected from the group consisting of saturated and unsaturated fatty acids having 10 to 20 carbon atoms and salts of these fatty acids.
  • the fatty acid is capric acid.
  • the amount of fatty acid used is, for example, 0.001% to 1% by weight, preferably 0.001% to 0.1% by weight, based on the total weight of the resulting dispersion. Preferably it is 0.005 mass% thru
  • the fatty acid used in this invention is at least 1 sort (s) selected from the said fatty acid group, These fatty acids can be used individually or in combination of 2 or more types.
  • the pigment or powder blended in the dispersion of the present invention is not particularly limited.
  • pigments include inorganic white pigments such as titanium dioxide and zinc oxide; inorganic red pigments such as red iron oxide (Bengara) and iron titanate; inorganic brown pigments such as ⁇ -iron oxide; yellow iron oxide and loess Inorganic black pigments such as black iron oxide and low-order titanium oxide; inorganic purple pigments such as mango violet and cobalt violet; inorganic green pigments such as chromium oxide, chromium hydroxide and cobalt titanate; Inorganic blue pigments such as ultramarine and bitumen; Titanium oxide coated mica, titanium oxide coated bismuth oxychloride chloride, titanium oxide coated talc, colored titanium oxide coated mica, bismuth oxychloride, fish scale foil, etc .; talc, sericite, mica , Constitutions such as kaolin, calcium carbonate, magnesium carbonate, silicic anhydride, barium
  • the powders include mica, talc, kaolin, sericite, montmorillonite, kaolinite, mica, muscovite, phlogopite, synthetic mica, sausage, mica, permiculite, magnesium carbonate, calcium carbonate, aluminum silicate, silica Barium, calcium silicate, magnesium silicate, strontium silicate, metal tungstate, magnesium, zeolite, barium sulfate, calcined calcium sulfate, tricalcium phosphate, calcium phosphate, fluorine apatite, hydroxyapatite, ceramic powder, bentonite, Smectite, clay, mud, metal soap (eg zinc myristate, calcium palmitate, aluminum stearate), calcium carbonate, bengara, yellow iron oxide, black iron oxide, ultramarine, bitumen, carbon black, Titanium fluoride, fine and ultrafine titanium oxide, zinc oxide, fine and ultrafine zinc oxide
  • Organic-inorganic composite powders are preferred.
  • the pigment or powder can be, for example, 25% by mass or less, preferably 20% by mass or less, with respect to the total mass of the dispersion.
  • the lower limit of the amount of pigment or powder is not particularly limited, but is, for example, about 0.001% by mass.
  • the said pigment or powder used in this invention is at least 1 type of the above-mentioned pigment group and powder group, These pigments or powder can be used individually or in combination of 2 or more types.
  • the dispersion of the present invention may further contain a polyhydric alcohol.
  • the polyhydric alcohol is a polyhydric alcohol different from the 1,2-alkanediol or 1,3-alkanediol listed above, and specific examples thereof include glycerin, propylene glycol, and polyethylene glycol.
  • polyethylene glycol having an average molecular weight of 1,000 to 4,000 can be preferably used.
  • the blending amount thereof is, for example, 1% by mass to 60% by mass, preferably 10% by mass to 30% by mass with respect to the total mass of the obtained dispersion. it can.
  • additives that can be generally used as cosmetic additives, quasi-drug additives, and pharmaceutical additives can be blended as necessary.
  • an additive component such as a physiologically active substance and a functional substance blended in a skin preparation for cosmetics, quasi-drugs or medicines, for example, an oily base, a moisturizer, a touch improver, a surfactant other than the above, Polymer, thickening / gelling agent, solvent, antioxidant, reducing agent, oxidizing agent, preservative, antibacterial agent, bactericidal agent, chelating agent, pH adjusting agent, acid, alkali, inorganic salt, UV absorber, whitening Agents, vitamins and derivatives thereof, hair growth agents, blood circulation promoters, stimulants, hormones, anti-wrinkle agents, anti-aging agents, squeeze agents, cooling sensation agents, warming sensation agents, wound healing promoters, irritation relaxation agents , Analgesic agent, cell activator, plant / animal / microbe extract,
  • oily bases examples include oleyl alcohol, jojoba alcohol, chimyl alcohol, ceralkyl alcohol, batyl alcohol, hexyl decanol, isostearyl alcohol, 2-octyldodecanol, dimer diol and other higher (polyhydric) alcohols; benzyl alcohol, etc.
  • Aralkyl alcohols and derivatives thereof isostearic acid, behenic acid, undecylenic acid, 12-hydroxystearic acid, palmitooleic acid, oleic acid, linoleic acid, linolenic acid, erucic acid, docosahexaenoic acid, eicosapentaenoic acid, isohexadecanoic acid, Antiisohenicosanoic acid, long-chain branched fatty acid, dimer acid, hydrogenated dimer acid, etc .; liquid paraffin (mineral oil), heavy liquid isoparaffin, light liquid isoparaffin, ⁇ -olefin Ligomers, polyisobutene, hydrogenated polyisobutene, polybutene, squalane, olive-derived squalane, squalene, petrolatum, solid paraffin, and other hydrocarbons; candelilla wax, carnauba wax, rice wax, wood wax, beeswax,
  • moisturizers / feel improvers include glycerin, trimethylolpropane, pentaerythritol, hexylene glycol, diglycerin, polyglycerin, diethylene glycol, dipropylene glycol, polypropylene glycol, ethylene glycol / propylene glycol copolymer and the like polyols and Polymers; glycol alkyl ethers such as diethylene glycol monoethyl ether (ethoxydiglycol), ethylene glycol monoethyl ether, ethylene glycol monobutyl ether, diethylene glycol dibutyl ether; (eicosane diacid / tetradecanedioic acid) polyglyceryl-10, tetradecane Water-soluble esters such as polyglyceryl-10; sorbitol, xylitol, erythritol, man Sugar alcohols such as tol and maltitol; glucose, fructose
  • Peptides Silylated peptides; Lactic acid bacteria culture, yeast extract, eggshell membrane protein, bovine submandibular gland mucin, hypotaurine, sesameignan glycoside, glutathione, Albumin, whey; choline chloride, phosphorylcholine; placenta extract, aerostin, collagen, aloe extract, hamamelis water, loofah water, chamomile extract, licorice extract, comfrey extract, silk extract, Izayoi rose extract, yarrow extract, eucalyptus extract Ceramides, such as animal and plant extract components such as merirot extract, natural ceramide (types 1, 2, 3, 4, 5, 6), hydroxyceramide, pseudoceramide, glycosphingolipid, ceramide and sugar ceramide-containing extract It is mentioned as preferable.
  • Ceramides such as animal and plant extract components such as merirot extract, natural ceramide (types 1, 2, 3, 4, 5, 6), hydroxyceramide
  • the surfactant include an anionic surfactant, a nonionic surfactant, a cationic surfactant, an amphoteric surfactant, and a polymer surfactant.
  • preferable surfactants include fatty acid salts such as potassium laurate and potassium myristate; alkyl sulfate esters such as sodium lauryl sulfate, triethanolamine lauryl sulfate, and ammonium lauryl sulfate; Polyoxyethylene alkyl sulfates such as sodium laureth sulfate and triethanolamine laureth sulfate; cocoyl methyl taurine sodium, cocoyl methyl taurine potassium, lauroyl methyl taurine sodium, myristoyl methyl taurine sodium, lauroyl methyl alanine sodium, lauroyl sarcosine sodium, lauroyl sarcosine tri Acyl N-methyl amino acid salts such as ethanolamine and sodium methylalanine sodium, la
  • Polyoxyethylene alkyl ethers with various polyoxyethylene addition numbers such as silethylene behenyl ethers), isosteares (polyoxyethylene isostearyl ether) s, octyldecesses (polyoxyethylene octyldodecyl ethers); Ether: Polyoxyethylene hydrogenated castor oil, polyoxyethylene castor oil, polyoxyethylene hydrogenated castor oil monoisostearate, polyoxyethylene hydrogenated castor oil triisostearate, polyoxyethylene hydrogenated castor oil monopyroglutamic acid monoisostearic acid diester Castor oil and hardened castor oil derivatives such as polyoxyethylene hydrogenated castor oil maleic acid; polyoxyethylene phytosterol; polyoxyethylene cholesterol Polyoxyethylene cholestanol; polyoxyethylene lanolin; polyoxyethylene reduced lanolin; polyoxyethylene / polyoxypropylene cetyl ether, polyoxyethylene / polyoxypropylene 2-decyltetradecyl ether, polyoxy
  • Polyglyceryl ethers polyoxyethylene alkylamines; tetrapolyoxyethylene / tetrapolyoxypropylene-ethylenediamine condensates; natural surfactants such as saponins and sophorolipids; polyoxyethylene fatty acid amides; Palm oil fatty acid monoethanolamide (cocamide MEA), palm oil fatty acid diethanolamide (cocamide DEA), lauric acid monoethanolamide (Lauramide MEA), lauric acid diethanolamide (lauramide DEA), lauric acid monoisopropanolamide (lauramide MIPA), palmitic acid monoethanolamide (partamide MEA), palmitic acid diethanolamide (partamide DEA), palm oil fatty acid methylethanolamide ( Fatty acid alkanolamides such as cocamidomethyl MEA); alkyldimethylamine oxides such as lauramine oxide, cocamamine oxide, stearamine oxide, and behenamine oxide; alkylethoxydimethylamine oxide; polyoxyethylene al
  • Nonionic surfactants of silicone, etc .; cationic surfactants include alkyltrimethylammonium chlorides such as behentrimonium chloride, steartrimonium chloride, cetrimonium chloride, lauryltrimonium chloride; stearyltrimonium bromide, etc.
  • Alkyltrimethylammonium bromides dialkyldimethylammonium chlorides such as distearyldimonium chloride and dicocodimonium chloride; fatty acid amidoamines and salts thereof such as stearamidepropyldimethylamine and stearamideethyldiethylamine; alkyl ethers such as stearoxypropyldimethylamine Amines and salts or quaternary salts thereof; ethyl sulfate long chain branched fatty acid (12-31) aminopropylethyldimethylammonium Fatty acid amide type quaternary ammonium salts such as lanolin fatty acid aminopropylethyldimethylammonium; polyoxyethylene alkylamines and salts or quaternary salts thereof; alkylamine salts; fatty acid amidoguanidinium salts; alkyl etheraminemonium salts; Benzalkonium salts; benzethonium salts
  • Silicone-based cationic surfactants such as amino-modified silicone, cation-modified silicone, cation-modified and polyether-modified silicone, amino-modified and polyether-modified silicone
  • amphoteric surfactant etc N-alkyl-N, N-dimethylamino acid betaines such as lauryl betaine (lauryldimethylaminoacetic acid betaine); fatty acid amide alkyl-N, N-dimethylamino acid betaines such as cocamidopropyl betaine and lauramidopropyl betaine; sodium cocoamphoacetate; Imidazoline-type betaines such as sodium lauroamphoacetate; alkylsulfobetaines such as alkyldimethyltaurine; sulfate-type betaines such as alkyldimethylaminoethanol sulfate; phosphate-type betaines such as alkyldimethylaminoethanol phosphate; phosphati
  • Polymers, thickeners and gelling agents include guar gum, locust bean gum, queens seed, carrageenan, galactan, arabic gum, tara gum, tamarind, far selelain, karaya gum, troarooi, cara gum, tragacanth gum, pectin, pectic acid and sodium Salt such as salt, salt such as alginic acid and sodium salt, mannan; starch such as rice, corn, potato, wheat; xanthan gum, dextran, succinoglucan, curdlan, hyaluronic acid and its salt, xanthan gum, pullulan, gellan gum, chitin , Chitosan, agar, gypsophila extract, chondroitin sulfate, casein, collagen, gelatin, albumin; methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypro Cellulose, hydroxypropylmethylcellulose, carboxymethylcellulose and salts thereof such as
  • Acrylic acid / methyl acrylate / methacrylamidopropyltrimethylammonium chloride copolymer such as polyquaternium-47, methacrylic acid choline ester polymer; cationized oligosaccharide, cationized dextran, guar hydroxypropyltri Cationic polysaccharides such as monium chloride; polyethyleneimine; cationic polymers; copolymers of 2-methacryloyloxyethyl phosphorylcholine such as polyquaternium-51 and copolymers of butyl methacrylate; acrylic resin emulsion, polyacrylic acid Polymer emulsions such as ethyl emulsion, polyacrylic alkyl ester emulsion, polyvinyl acetate resin emulsion, natural rubber latex, synthetic latex; nitrocellulose; Tans and various copolymers; Various silicones; Various silicone-based copolymers such as acrylic-silicone graft
  • Solvents include lower alcohols such as ethanol, 2-propanol (isopropyl alcohol), butanol and isobutyl alcohol; glycols such as propylene glycol, diethylene glycol, dipropylene glycol and isopentyl diol; diethylene glycol monoethyl ether (ethoxydiglycol) , Glycol ethers such as ethylene glycol monoethyl ether, ethylene glycol monobutyl ether, triethylene glycol monoethyl ether, diethylene glycol diethyl ether, diethylene glycol dibutyl ether, propylene glycol monoethyl ether, dipropylene glycol monoethyl ether; ethylene glycol monoethyl ether Acetate, diethylene glycol Glycol ether esters such as ethyl ether acetate and propylene glycol monoethyl ether acetate; glycol esters such as diethoxyethyl succinate and ethylene
  • Antioxidants include tocopherol derivatives such as tocopherol (vitamin E) and tocopherol acetate; BHT, BHA; gallic acid derivatives such as propyl gallate; vitamin C (ascorbic acid) and / or derivatives thereof; erythorbic acid and derivatives thereof; Preferred are sulfites such as sodium sulfite; bisulfites such as sodium bisulfite; thiosulfates such as sodium thiosulfate; metabisulfites; thiotaurine, hypotaurine; thioglycerol, thiourea, thioglycolic acid, cysteine hydrochloride As mentioned.
  • Preferred examples of the reducing agent include thioglycolic acid, cysteine, cysteamine and the like.
  • Preferred examples of the oxidizing agent include hydrogen peroxide water, ammonium persulfate, sodium bromate, percarbonate, and the like.
  • preservatives, antibacterial agents, and bactericides include hydroxybenzoic acid such as methylparaben, ethylparaben, propylparaben, and butylparaben, and salts or esters thereof; salicylic acid; sodium benzoate; phenoxyethanol; methylchloroisothiazolinone, methylisothiazo Isothiazolinone derivatives such as linone; imidazolinium urea; dehydroacetic acid and its salts; phenols; halogenated bisphenols such as triclosan, acid amides, quaternary ammonium salts; trichlorocarbanide, zinc pyrithione, benzalkonium chloride, chloride Benzethonium, sorbic acid, chlorhexidine, chlorhexidine gluconate, halocarban, hexachlorophene, hinokitiol; phenol, isopropylphenol, cresol, Mall
  • chelating agents include edetate (ethylenediaminetetraacetate) such as EDTA, EDTA2Na, EDTA3Na, and EDTA4Na; hydroxyethylethylenediaminetriacetate such as HEDTA3Na; pentetate (diethylenetriaminepentaacetate); phytic acid; Phosphonic acid and its sodium salt; polyamino acids such as polyaspartic acid and polyglutamic acid; sodium polyphosphate, sodium metaphosphate, phosphoric acid; sodium citrate, citric acid, alanine, dihydroxyethylglycine, gluconic acid, Ascorbic acid, succinic acid and tartaric acid are preferred.
  • edetate ethylenediaminetetraacetate
  • HEDTA3Na EDTA3Na
  • EDTA4Na hydroxyethylethylenediaminetriacetate
  • pentetate diethylenetriaminepentaacetate
  • phytic acid
  • pH adjusters / acids / alkalis include ascorbic acid, citric acid, sodium citrate, lactic acid, sodium lactate, potassium lactate, glycolic acid, succinic acid, acetic acid, sodium acetate, malic acid, tartaric acid, fumaric acid, phosphoric acid, Hydrochloric acid, sulfuric acid, monoethanolamine, diethanolamine, triethanolamine, isopropanolamine, triisopropanolamine, 2-amino-2-methyl-1,3-propanediol, 2-amino-2-hydroxymethyl-1,3-propane Preferred examples include diol, arginine, sodium hydroxide, potassium hydroxide, aqueous ammonia, guanidine carbonate, and ammonium carbonate.
  • Inorganic salts include sodium chloride-containing salts such as salt, common salt, rock salt, sea salt, natural salt; potassium chloride, aluminum chloride, calcium chloride, magnesium chloride, bittern, zinc chloride, ammonium chloride; sodium sulfate, aluminum sulfate, Aluminum sulfate / potassium sulfate (alum), aluminum sulfate / ammonium sulfate, barium sulfate, calcium sulfate, potassium sulfate, magnesium sulfate, zinc sulfate, iron sulfate, copper sulfate; sodium phosphates such as 1Na, 2Na and 3Na phosphates, phosphoric acid Potassium, calcium phosphates and magnesium phosphates are preferred.
  • sodium chloride-containing salts such as salt, common salt, rock salt, sea salt, natural salt
  • potassium chloride aluminum chloride, calcium chloride, magnesium chloride, bittern, zinc chloride, ammonium chlor
  • ultraviolet absorbers examples include paraaminobenzoic acid, paraaminobenzoic acid monoglycerin ester, N, N-dipropoxyparaaminobenzoic acid ethyl ester, N, N-diethoxyparaaminobenzoic acid ethyl ester, and N, N-dimethylparaaminobenzoic acid ethyl ester.
  • Benzoic acid ultraviolet absorbers such as esters, N, N-dimethylparaaminobenzoic acid butyl ester, N, N-dimethylparaaminobenzoic acid methyl ester; Anthranilic acid ultraviolet absorbers such as homomenthyl-N-acetylanthranilate; Salicylic acid And salicylic acid systems such as sodium salt, amyl salicylate, menthyl salicylate, homomenthyl salicylate, octyl salicylate, phenyl salicylate, benzyl salicylate, p-isopropanol phenyl salicylate External line absorbent: octyl cinnamate, ethyl-4-isopropyl cinnamate, methyl-2,5-diisopropyl cinnamate, ethyl-2,4-diisopropyl cinnamate, methyl-2,4-diisopropyl c
  • UV absorbers 3- (4′-methylbenzylidene) -d, l-camphor, 3-benzylidene-d, l-camphor; 2-phenyl-5-methylbenzoxazole; 2,2′-hydroxy- 2- (2′-hydroxy-5′-t-octylphenyl) benzotriazole; 2- (2′-hydroxy-5′-methylphenylbenzotriazole; dibenzalazine; dianisoylmethane; 5- (3,3-dimethyl-2-norbornylidene) -3-pentan-2-one; dibenzoylmethane derivatives such as 4-t-butylmethoxydibenzoylmethane; octyl triazone; urocanic acid such as urocanic acid and ethyl urocanate Derivatives; 2- (2′-hydroxy-5′-methylphenyl) benzotriazole Hydantoin derivatives such as 1- (3,4-dimethoxypheny
  • whitening agents include hydroquinone glycosides such as arbutin and ⁇ -arbutin and their esters; ascorbic acid phosphates such as ascorbic acid, sodium ascorbic acid phosphate and magnesium ascorbic acid phosphate, ascorbic acid Ascorbic acid fatty acid esters such as tetraisopalmitic acid ester, ascorbic acid alkyl ethers such as ascorbic acid ethyl ether, ascorbic acid glucosides such as ascorbic acid-2-glucoside and fatty acid esters thereof, ascorbic acid sulfate ester, tocopheryl ascorbyl phosphate Ascorbic acid derivatives such as kojic acid, ellagic acid, tranexamic acid and its derivatives, ferulic acid and its derivatives, placenta extract, glutathione, oryzanol, butylreso Shinoru, oil-soluble Kamomiraekisu, oil-soluble licorice extract,
  • Vitamins and their derivatives include vitamin A such as retinol, retinol acetate, retinol palmitate; thiamine hydrochloride, thiamine sulfate, riboflavin, riboflavin acetate, pyridoxine hydrochloride, pyridoxine dioctanoate, pyridoxine dipalmitate, Flavin adenine dinucleotide, cyanocobalamin, folic acid, nicotinic acid such as nicotinic acid amide / benzyl nicotinate, vitamin B group such as choline; vitamin C such as ascorbic acid and its sodium salt; vitamin D; ⁇ , Vitamin E such as ⁇ , ⁇ , and ⁇ -tocopherol; other vitamins such as pantothenic acid and biotin; ascorbic acid phosphates such as ascorbic acid phosphate sodium salt and ascorbic acid phosphate magnesium salt, Ascorbic acid fatty acid esters
  • Plant extracts and tinctures such as assembly extract, red pepper tincture, ginger tincture, ginger extract, cantalis tincture; capsaicin, nonylic acid vanillylamide, gingeron, ictamol, tannic acid Borneol, cyclandrate, cinnarizine, trazoline, acetylcholine, verapamil, cephalanthin, ⁇ -oryzanol, vitamin E and derivatives such as tocopherol / nicotinic acid tocopherol, ⁇ -oryzanol, nicotinic acid, nicotinic acid amide, nicotinic acid benzyl ester, Inositol hexanicotinate, derivatives such as nicotine alcohol, allantoin, photosensitive element 301, photosensitive element 401, capronium chloride, pentadecanoic acid monoglyceride, flavonol Derivatives, stigmasterol or stigmasterol and its glycoside
  • hormones include estradiol, estrone, ethinyl estradiol, cortisone, hydrocortisone, prednisone and the like.
  • Other remedies such as anti-wrinkle agents, anti-aging agents, squeeze agents, cooling sensations, warming sensation agents, wound healing promoters, irritation relievers, analgesics, cell activators include retinols, retinoic acids, retinoin Acid tocopheryl; derivatives such as lactic acid, glycolic acid, gluconic acid, fruit acid, salicylic acid and glycosides / esterified products thereof, ⁇ - or such as hydroxycapric acid, long chain ⁇ -hydroxy fatty acid, long chain ⁇ -hydroxy fatty acid cholesteryl ⁇ -hydroxy acids and derivatives thereof; ⁇ -aminobutyric acid, ⁇ -amino- ⁇ -hydroxybutyric acid; carnitine; carnosine; creatine; ceramides, sphingosines; caffeine, xant
  • Antioxidant / active oxygen scavengers include catechins; flavones such as quercetin; isoflavones; gallic acid and ester sugar derivatives; polyphenols such as tannin, sesamin, protoanthocyanidin, chlorogenic acid, apple polyphenol; rutin and glycosides, etc.
  • Plant / animal / microbe extracts include iris extract, ashitaba extract, asunalo extract, asparagus extract, avocado extract, achacha extract, almond extract,retea extract, arnica extract, aloe extract, apricot extract, apricot kernel extract, ginkgo biloba extract , Chinchilla extract, fennel extract, ginseng extract, turmeric extract, oolong tea extract, walnut extract, ages extract, echinacea leaf extract, enme extract, gonon extract, duckweed extract, pollen extract, barley extract, ginseng extract, hypericum extract , Nettle extract, onionis extract, Dutch mustard extract, orange extract, dried sea water, seaweed extract, oyster leaf extract, oyster extract, hydrolyzed elastin, water Dehydrated wheat powder, hydrolyzed silk, cocoon extract, chamomile extract, oil-soluble chamomile extract, carrot extract, cormorant mugwort extract, oat extract, calcade extract, licorice extract, oil-soluble lic
  • antipruritic agents examples include diphenhydramine hydrochloride, chlorpheniramine maleate, camphor, substance-P inhibitor, and the like.
  • exfoliating / dissolving agent examples include salicylic acid, sulfur, resorcin, selenium sulfide, pyridoxine and the like.
  • antiperspirants examples include chlorohydroxyaluminum, aluminum chloride, zinc oxide, zinc paraphenol sulfonate, and the like.
  • Examples of the refreshing agent include menthol and methyl salicylate.
  • astringents include citric acid, tartaric acid, lactic acid, aluminum sulfate / potassium, and tannic acid.
  • Enzymes include superoxide dismutase, catalase, lysozyme chloride, lipase, papain, pancreatin, protease, and the like.
  • Preferred nucleic acids include ribonucleic acid and its salts, deoxyribonucleic acid and its salts, and adenosine triphosphate disodium.
  • Orange No. 201 Orange No. 203, Orange No. 204, Orange No. 205, Orange No. 206, Orange No. 207, Orange No. 401, Orange No. 402, Orange No. 403, Yellow No. 201, Yellow No. 202-1 Yellow 202-2, Yellow 203, Yellow 204, Yellow 205, Yellow 4, Yellow 401, Yellow 402, Yellow 403-1, Yellow 404, Yellow 405, Yellow 406, Yellow Legal pigments such as No. 407 and Yellow No.
  • Anti-inflammatory / anti-inflammatory agents include glycyrrhizic acid and its derivatives, glycyrrhetinic acid derivatives, salicylic acid derivatives, hinokitiol, guaiazulene, allantoin, indomethacin, ketoprofen, ibuprofen, diclofenac, loxoprofen, celecoxib, infliximab, etanercept, zinc oxide, hydroacetic acid, zinc acetate, Preferred examples include prednisone, diphedramine hydrochloride, chlorpheniramine maleate; and plant extracts such as peach leaf extract and persimmon leaf extract.
  • Anti-asthma, anti-chronic obstructive pulmonary disease, anti-allergy, immunomodulators include aminophylline, theophylline, steroids (fluticasone, beclomethasone, etc.), leukotriene antagonists, thromboxane inhibitors, intal, ⁇ 2-stimulant (Formoterol, salmeterol, albuterol, tulobuterol, clenbuterol, epinephrine, etc.), tiotropium, ipratropium, dextromethorphan, dimemorphan, bromhexine, tranilast, ketotifen, azelastine, cetirizine, chlorpheniramine, polyquitolsine, Preferred examples include cytokine regulators, interferons, omalizumab, and protein / antibody preparations.
  • Preferred examples of the anti-infective and antifungal agents include oseltamivir, zanamivir, and itraconazole.
  • cosmetic raw material standards cosmetic ingredient-specific combination ingredient standards, Japan Cosmetic Industry Association ingredient display name list, INCI dictionary (The International Cosmetic Ingredients and Handbooks), quasi-drug ingredients standards, Japanese pharmacopoeia, pharmaceutical additive standards Ingredients listed in the Food Addendum, etc., and the international patent classification IPC described in Japan and other foreign patent gazettes and patent publications (including publications and republications) belonging to the A61K7 and A61K8 classifications It is possible to contain known cosmetic ingredients, pharmaceutical ingredients, food ingredients, etc., in known combinations, blending ratios and blending amounts.
  • the dispersion of the present invention is a pigment or powder dispersant comprising a lipid peptide compound comprising at least one of the compounds represented by the formulas (1) to (3) or a pharmaceutically usable salt thereof. And at least one selected from the group consisting of surfactants, water, 1,2-alkanediols or 1,3-alkanediols, fatty acids, pigments and powders, and optionally other additives such as polyhydric alcohols These are mixed and stirred with heating, and then stirred and cooled to about room temperature.
  • the dispersion of the present invention is produced by the following process as an example. a) a step of blending the above-mentioned pigment or powder dispersant (lipid peptide compound), a surfactant, and water, and heating to prepare a solution (or dispersion); b) adding the solution (or dispersion) to water and heating at a temperature of room temperature to less than 100 ° C .; c) A step of cooling with stirring until the temperature is lower than the temperature in the heating step to obtain the dispersion of the present invention.
  • At least one selected from the group consisting of 1,2-alkanediol or 1,3-alkanediol, fatty acid, and pigment and powder, and the other components are the solution (or dispersion) in step a). It may be added in the preparation step, or may be added in advance to the water to which the solution (or dispersion) is added in step b). Further, water is 60% by mass or more and 99.9% by mass or less based on the total mass of the dispersion liquid (including at least one selected from the group consisting of pigment and powder) of the present invention thus obtained. preferable.
  • the heating temperature in the step a) and the step b) is preferably 50 ° C. to 90 ° C., more preferably 60 ° C. to 90 ° C., for example 80 ° C., and stirring is preferably performed while heating.
  • the heating and stirring time in each step at this time varies depending on the pigment or powder dispersant (lipid peptide compound) used, the type of the surfactant and other components, and the blending amount thereof, but usually from 1 minute to 50 minutes. It can be dissolved and dispersed in about minutes.
  • cooling is performed with stirring until the liquid temperature is lower than the temperature in step b) (step c).
  • the cooling temperature is, for example, room temperature to 80 ° C., room temperature to 60 ° C., or room temperature to 40 ° C.
  • the dispersion liquid of this invention can also be manufactured by adding another compounding component to this premix suitably.
  • the following is mentioned as a manufacturing method of the dispersion liquid which passed through the premix.
  • Step for preparing premix 1-1) Surfactant and water, pigment or powder dispersant (compound represented by the above formulas (1) to (3) or pharmaceutically usable thereof)
  • a step of appropriately adding 1,2-alkanediol or 1,3-alkanediol, fatty acid and other additives to the heated mixed system, 1-3)
  • the aqueous composition (premix) heated to a temperature of room temperature to less than 100 ° C.
  • aqueous phase in an aqueous phase heated to a temperature of room temperature to less than 100 ° C.
  • Process, 2-2) A cooling step in which the mixture obtained in the mixing step is stirred and cooled to obtain a dispersion.
  • the aqueous phase in the above step 2-1) contains water, may further contain higher alcohols and pigments, and may contain 1,2-alkanediol or 1,3-alkanediol, fatty acids, and other additives. .
  • a pigment and other additives may be mixed with the aqueous composition (premix) and then combined with the aqueous phase. Furthermore, in the mixing step, a dispersion (preparation) to which a drug is added can also be produced by adding a drug solution.
  • the heating temperature of the mixed system (and aqueous composition) in the steps 1-1) and 1-2) is preferably 50 ° C. to 90 ° C., more preferably 60 ° C. to 90 ° C., for example 70 ° C., or 80 ° C. It is.
  • This step is preferably carried out with stirring.
  • the heating (stirring) time in each step at this time varies depending on the types of pigments, powder dispersants (lipid peptide compounds), surfactants and other components contained in the aqueous composition, and the blending amount thereof. Usually, about 5 to 50 minutes. By this step, the aqueous composition is uniformly dissolved.
  • the cooling temperature in the step 1-3) is, for example, room temperature to 80 ° C., room temperature to 60 ° C., or room temperature to 40 ° C. In this step, it is more preferable to cool with stirring, and then stop stirring and leave still. In addition, it is preferable that water is 30 mass% or more and less than 80 mass% with respect to the total mass of the aqueous composition (premix) obtained by the 1) process.
  • the heating temperature of the aqueous phase and the aqueous composition (premix) is preferably 50 ° C. to 90 ° C., more preferably 60 ° C. to 90 ° C., such as 70 ° C., or 80 ° C., or 90 ° C. It is.
  • the aqueous phase is preferably heated with stirring because it contains other components, and it is usually preferred to carry out heating (stirring) for about 1 to 50 minutes until the contained components are uniformly dissolved and dispersed.
  • the heating temperature of the aqueous phase may be the same as the heating temperature of the aqueous composition (premix).
  • the mixture obtained in the previous step is stirred and cooled to obtain a dispersion.
  • stirring may be performed until the cooling temperature reaches room temperature to 80 ° C., room temperature to 60 ° C., for example, about 60 ° C., and then stirring may be stopped and allowed to stand and cool.
  • the blending amount of water is preferably 60% by mass or more and 99.9% by mass or less with respect to the total mass of the dispersion.
  • the obtained solid was dissolved in 120 g of tetrahydrofuran and 60 g of acetonitrile, heated to 60 ° C., stirred for 1 hour, cooled, and filtered.
  • the solid obtained here was washed with 120 g of water, dried under reduced pressure after filtration, and 26.9 g (yield 65) of white crystals of N-palmitoyl-Gly-His free form (hereinafter also simply referred to as “Pal-GH”). %).
  • Example 1 Preparation of liquid foundation containing 10% by mass of pigment
  • a liquid foundation containing 10% by mass of pigment was prepared.
  • a Laboran screw tube No. 7, As One Co., Ltd.
  • 5.0 g of pigment and 33.0 g of pure water were stirred at 80 ° C. for 2 minutes and heated to 80 ° C. with 1,2-hexane.
  • 1.0 g of diol was added and stirred for 2 minutes.
  • 1.0 g of the composition [1] heated to 80 ° C. was added and stirred for 2 minutes, then 10.0 g of glycerin heated to 80 ° C. was added and stirred for 3 minutes, and the temperature reached room temperature.
  • Composition [1] has the composition shown in Table 1 and is mixed with Pal-GH, polyoxyethylene lauryl ether, and purified water, heated and stirred at 70 ° C., and 1,2-hexanediol and stearic acid were added thereto. The mixture was further stirred at 70 ° C. and then allowed to cool to room temperature. Also in the following examples, the composition [1] obtained by the same procedure was used. All stirring in the above manufacturing process was performed at 400 rpm.
  • Example 2 Preparation of 10% by mass pigment white water powder foundation
  • a white powder foundation containing 10% by mass of the pigment shown in Table 1 was produced in the same procedure as in Example 1 except that 0.5 g of the composition [1] and 33.5 g of pure water were used.
  • Example 3 Preparation of a white powder foundation containing 15% by mass of pigment
  • a white powder foundation containing 15% by mass of the pigment shown in Table 1 was produced in the same procedure as in Example 2 except that 7.5 g of the pigment and 31 g of pure water were used.
  • Comparative Example 1 A foundation of a comparative example in which 10% by mass of the pigment shown in Table 1 was blended was prepared in the same procedure as in Example 1 except that the composition [1] was not blended and the pure water was changed to 34.0 g.
  • FIG. 1 shows the foundations (appearance) of Examples 1 to 3 and Comparative Example 1.
  • Examples 1 to 3 in which the composition [1] containing Pal-GH was blended, the pigment was scattered and the dispersion stability of the pigment was confirmed. Further, by adjusting the blending amount of the composition [1] containing Pal-GH, a liquid foundation type with high viscosity (Example 1) and a white powder foundation type with low viscosity (Example 2 and Example) Example 3) could be prepared.
  • Comparative Example 1 in which the composition [1] containing Pal-GH was not blended as shown in FIG. 1, the pigment and other components were separated, resulting in precipitation of the pigment.
  • Example 4 Preparation of dispersion liquid containing 2% by mass of pearl pigment
  • Table 2 a dispersion containing 2% by mass of pearl pigment was prepared.
  • 1.0 g of pearl pigment and 33.5 g of pure water were stirred at 80 ° C. for 2 minutes, and then heated to 80 ° C.
  • 5.0 g of butylene glycol (1,3-butanediol) was added and mixed with stirring for 2 minutes.
  • 0.5 g of composition [1] heated to 80 ° C. was added and mixed with stirring for 2 minutes, then 10.0 g of glycerin heated to 80 ° C. was added and mixed for 3 minutes, and the temperature reached room temperature.
  • the solution was stirred and cooled to obtain a dispersion. All stirring in the above manufacturing process was performed at 400 rpm.
  • Example 5 Preparation of 0.5% by mass of pearl pigment dispersion
  • a dispersion liquid containing 0.5% by mass of a pearl pigment was prepared.
  • 0.25 g of pearl pigment and 49.25 g of pure water were stirred at 80 ° C. for 2 minutes and heated to 80 ° C.
  • the mixture was stirred and cooled to room temperature as it was to obtain a dispersion. All stirring in the above manufacturing process was performed at 400 rpm.
  • FIG. 2 shows pearl pigment-containing dispersions (appearance) of Examples 4 and 5 and Comparative Example 2.
  • Comparative Example 2 in which the composition [1] containing Pal-GH was not blended, the pearl pigment and other components were separated, resulting in precipitation of the pearl pigment.
  • Example 4 and Example 5 in which the composition [1] was blended, the dispersibility of the pearl pigment was improved.
  • Example 6 Preparation of tricalcium phosphate dispersion
  • Table 3 a dispersion containing 0.5% by mass of tricalcium phosphate was prepared.
  • a composition obtained by stirring 0.25 g of tricalcium phosphate and 49.25 g of pure water at 80 ° C. for 2 minutes in a Laborun screw tube bottle (No. 7, As One Co., Ltd.) and heating it to 80 ° C. [1] After adding 0.5 g and stirring and mixing for 2 minutes, the mixture was stirred and cooled to room temperature as it was to obtain a dispersion. All stirring in the above manufacturing process was performed at 400 rpm.
  • Comparative Example 3 A comparative example in which 0.5% by mass of tricalcium phosphate shown in Table 3 was blended in the same procedure as in Example 5 except that the composition [1] was not blended and the pure water was 49.75 g. A dispersion was prepared.
  • FIG. 3 shows the tricalcium phosphate blend dispersion (appearance) of Example 6 and Comparative Example 3.
  • Comparative Example 3 in which the composition [1] containing Pal-GH was not blended, tricalcium phosphate and other components were separated, resulting in precipitation of tricalcium phosphate.
  • Example 6 containing the composition [1] the dispersibility of tricalcium phosphate was improved.
  • Example 7 Production of 0.01% by mass of gold foil mixed dispersion
  • a dispersion liquid containing 0.01% by mass of gold foil (approximately 2 mm square to 10 mm square) was prepared.
  • Example 8 Preparation of 0.05 mass% dispersion of gold foil
  • a dispersion containing 0.05% by mass of the gold foil shown in Table 4 was prepared in the same manner as in Example 7 except that 25 mg of the gold foil, 0.5 g of the composition [1] and 49.475 g of pure water were used. Manufactured.
  • Comparative Example 4 A dispersion of a comparative example in which 0.01% by mass of the gold foil shown in Table 4 was blended in the same procedure as in Example 7 except that the composition [1] was not blended and the pure water was 49.95 g. Prepared.
  • FIG. 4 shows the gold foil-containing dispersion (appearance) of Examples 7 and 8 and Comparative Example 4.
  • Comparative Example 4 in which the composition [1] containing Pal-GH was not blended, the gold foil and other components were separated, and the gold foil floated or precipitated depending on its weight.
  • the dispersibility of tricalcium phosphate was improved.
  • Example 9 Preparation of 17% by mass of pigment and preparation of O / W liquid foundation
  • Table 5 a foundation in which 17% by mass of pigment was uniformly dispersed was prepared.
  • a 200 mL beaker made by HARIO
  • 34.0 g of pigment fresh color base aqua
  • 139.6 g of purified water
  • 0.2 g of sodium N-stearoylmethyl taurine NIKKOL SMT, Nikko Chemicals
  • LPA lecithin
  • 0.2 g of Nikko Chemicals Co., Ltd. 0.2 g of EDTA-2Na (Pure Chemical Co., Ltd.)
  • 0.4 g of hydroxypropylcellulose Nippon Soda Co., Ltd.
  • xanthan gum KELTROL-CG-ST, 0.4 g of Sanki Co., Ltd.
  • phase B was mixed and heated and stirred at 75 ° C. for 10 minutes (phase B).
  • NIKKOL Nicomulus 41 Nikko Chemicals Co., Ltd.
  • NIKKOL NATURAL OILS Nikko Chemicals Co., Ltd.
  • NIKKOL Nicoguard 88 Nikko Chemicals Co., Ltd. 1 0.0 g was added and stirred with heating at 75 ° C. for 10 minutes (phase A).
  • Phase A was added to Phase B with slow stirring, and the resulting mixture was added at 75 ° C.
  • phase B was mixed and heated and stirred at 75 ° C. for 10 minutes (phase B).
  • NIKKOL Nicomulus 41 Nikko Chemicals Co., Ltd.
  • NIKKOL NATURAL OILS Nikko Chemicals Co., Ltd.
  • NIKKOL Nicoguard 88 Nikko Chemicals Co., Ltd. 1 0.0 g was added and stirred with heating at 75 ° C. for 10 minutes (phase A).
  • Phase A was added to Phase B with slow stirring, and the resulting mixture was added at 75 ° C.
  • FIG. 5 shows the results of pigment dispersibility evaluation by observation (photograph) of a polarizing microscope (manufactured by Olympus Corporation) of the O / W liquid foundation of Example 9 and Comparative Example 5.
  • a polarizing microscope manufactured by Olympus Corporation
  • FIG. 6 shows the O / W liquid foundation (appearance) of Example 9 and Comparative Example 5 after the liquid foundation was prepared and stored for one month.
  • Comparative Example 5 in which the composition [1] containing Pal-GH was not blended, separation of the pigment and oil was observed (in the figure, the separation state was uneven color). Observed), the dispersibility was non-uniform, but in Example 9 in which the composition [1] was blended, the dispersibility of the pigment was improved.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Cosmetics (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)

Abstract

Le problème décrit par la présente invention est de fournir : un liquide de dispersion contenant un pigment ou une poudre, dont la séparation et la sédimentation du pigment ou similaire peut être empêchée dans le temps ; et un dispersant. La solution selon l'invention porte sur un liquide de dispersion qui contient : un dispersant pour des pigments ou des poudres, qui est formé d'un composé de peptide et de lipide qui est composé d'au moins un composé choisi parmi les composés représentés par la formule (1), leurs analogues et leurs sels pharmaceutiquement acceptables ; un tensioactif ; de l'eau ; du 1,2-alcanediol ou du 1,3-alcanediol ; un acide gras ; et au moins une substance choisie dans le groupe constitué par les pigments et les poudres. L'invention concerne également le dispersant décrit ci-dessus pour des pigments ou des poudres. (Dans la formule : R1 représente un groupe aliphatique ayant 9 à 23 atomes de carbone ; R2 représente un atome d'hydrogène ou un groupe alkyle ayant 1 à 4 atomes de carbone, qui peut avoir une chaîne ramifiée ayant 1 ou 2 atomes de carbone ; R3 représente un groupe –(CH2)n-X ; n représente un nombre de 1 à 4 ; X représente un groupe amino, un groupe guanidino, un groupe –CONH2 ou un noyau hétérocyclique condensé qui est composé d'un cycle à cinq chaînons et/ou d'un cycle à six chaînons, qui peuvent avoir 1 à 3 atomes d'azote. )
PCT/JP2018/015275 2017-04-12 2018-04-11 Liquide de dispersion contenant un dispersant pour pigments ou poudres Ceased WO2018190383A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019512559A JPWO2018190383A1 (ja) 2017-04-12 2018-04-11 顔料又は粉体用分散剤を含有する分散液

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017079128 2017-04-12
JP2017-079128 2017-04-12

Publications (1)

Publication Number Publication Date
WO2018190383A1 true WO2018190383A1 (fr) 2018-10-18

Family

ID=63793228

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2018/015275 Ceased WO2018190383A1 (fr) 2017-04-12 2018-04-11 Liquide de dispersion contenant un dispersant pour pigments ou poudres

Country Status (3)

Country Link
JP (1) JPWO2018190383A1 (fr)
TW (1) TW201902451A (fr)
WO (1) WO2018190383A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113957730A (zh) * 2021-12-13 2022-01-21 高阳县信誉印染有限公司 一种织物用印染剂及其印染工艺

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014003015A1 (fr) * 2012-06-25 2014-01-03 日産化学工業株式会社 Liquide de dispersion et procédé de formation d'un hydrogel
WO2015099074A1 (fr) * 2013-12-25 2015-07-02 日産化学工業株式会社 Matériau de base en forme de bâtonnet contenant un composé de peptide lipidique
WO2016121867A1 (fr) * 2015-01-28 2016-08-04 国立大学法人九州大学 Matériau de base absorbable par voie transdermique comprenant un composé de type peptide lipidique
WO2016121822A1 (fr) * 2015-01-28 2016-08-04 国立大学法人九州大学 Matériau de base hydratant comprenant un composé lipide-peptide
JP2016193840A (ja) * 2015-03-31 2016-11-17 株式会社ナリス化粧品 水性ゲル状化粧料
JP2016193836A (ja) * 2015-03-31 2016-11-17 株式会社ナリス化粧品 固形化粧料
WO2016208460A1 (fr) * 2015-06-24 2016-12-29 日産化学工業株式会社 Procédé d'ajustement de dureté de matériau de base en bâtonnet comprenant un composé peptide lipidique
WO2016208442A1 (fr) * 2015-06-24 2016-12-29 日産化学工業株式会社 Matériau de base en bâtonnet contenant un composé peptide lipidique

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014003015A1 (fr) * 2012-06-25 2014-01-03 日産化学工業株式会社 Liquide de dispersion et procédé de formation d'un hydrogel
WO2015099074A1 (fr) * 2013-12-25 2015-07-02 日産化学工業株式会社 Matériau de base en forme de bâtonnet contenant un composé de peptide lipidique
WO2016121867A1 (fr) * 2015-01-28 2016-08-04 国立大学法人九州大学 Matériau de base absorbable par voie transdermique comprenant un composé de type peptide lipidique
WO2016121822A1 (fr) * 2015-01-28 2016-08-04 国立大学法人九州大学 Matériau de base hydratant comprenant un composé lipide-peptide
JP2016193840A (ja) * 2015-03-31 2016-11-17 株式会社ナリス化粧品 水性ゲル状化粧料
JP2016193836A (ja) * 2015-03-31 2016-11-17 株式会社ナリス化粧品 固形化粧料
WO2016208460A1 (fr) * 2015-06-24 2016-12-29 日産化学工業株式会社 Procédé d'ajustement de dureté de matériau de base en bâtonnet comprenant un composé peptide lipidique
WO2016208442A1 (fr) * 2015-06-24 2016-12-29 日産化学工業株式会社 Matériau de base en bâtonnet contenant un composé peptide lipidique

Also Published As

Publication number Publication date
TW201902451A (zh) 2019-01-16
JPWO2018190383A1 (ja) 2020-02-27

Similar Documents

Publication Publication Date Title
JP6274440B2 (ja) 分散液及びヒドロゲル形成方法
JP6132108B2 (ja) ヒドロゲル形成材料、プレミックス及びヒドロゲル形成方法
KR102292009B1 (ko) 분산액 및 하이드로겔 형성방법
US11771645B2 (en) Transdermally absorbable base material containing lipid peptide compound
JP6624380B2 (ja) 脂質ペプチド型化合物を含有するスティック状基材
JP6734568B2 (ja) 脂質ペプチド型化合物を含有するスティック状基材
JP6802711B2 (ja) 脂質ペプチド型化合物を含有する保湿基材
JP2015051961A (ja) 経皮吸収基材
JP6613486B2 (ja) 脂質ペプチド型化合物を含有する増粘性組成物
JP6694166B2 (ja) 脂質ペプチド型化合物を含有するスティック状基材の硬度調整方法
JP6660034B2 (ja) 脂質ペプチド型化合物を含むスティック状基材
WO2018117156A1 (fr) Base de préparation solide de type bâton pour application externe sur la peau
KR20200108447A (ko) 분체를 포함하는 조성물
WO2018190383A1 (fr) Liquide de dispersion contenant un dispersant pour pigments ou poudres
WO2018207947A1 (fr) Matériau de base en forme de bâtonnet contenant un polysaccharide
WO2018207948A1 (fr) Matériau de base en forme de bâtonnet et à teneur élevée en eau

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18784536

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2019512559

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18784536

Country of ref document: EP

Kind code of ref document: A1